Lopes S, Alves M, Rodrigues P
Cureus. 2022; 14(9):e29130.
PMID: 36258959
PMC: 9560002.
DOI: 10.7759/cureus.29130.
Bonilla Gonzalez C, Rusinque J, Uribe C, Carias A, Contreras M
J Med Cases. 2021; 12(5):195-201.
PMID: 34434457
PMC: 8383534.
DOI: 10.14740/jmc3535.
Raj N, Reidy-Lagunes D
Hematol Oncol Clin North Am. 2015; 30(1):119-33.
PMID: 26614372
PMC: 5046222.
DOI: 10.1016/j.hoc.2015.09.005.
Pea A, Hruban R, Wood L
Expert Rev Gastroenterol Hepatol. 2015; 9(11):1407-19.
PMID: 26413978
PMC: 4890468.
DOI: 10.1586/17474124.2015.1092383.
Oladejo A
Ann Ib Postgrad Med. 2014; 7(2):29-33.
PMID: 25161467
PMC: 4111010.
DOI: 10.4314/aipm.v7i2.64085.
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?.
Reidy-Lagunes D, Thornton R
Curr Oncol Rep. 2012; 14(3):249-56.
PMID: 22434313
DOI: 10.1007/s11912-012-0232-1.
Octreotide-treated diabetes accompanied by endogenous hyperinsulinemic hypoglycemia and protein-losing gastroenteropathy.
Takahashi N, Nagamine M, Fukuda M, Motomura W, Abiko A, Haneda M
Case Rep Med. 2011; 2011:381203.
PMID: 21826148
PMC: 3150201.
DOI: 10.1155/2011/381203.
Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.
Kulke M, Bendell J, Kvols L, Picus J, Pommier R, Yao J
J Hematol Oncol. 2011; 4:29.
PMID: 21672194
PMC: 3128039.
DOI: 10.1186/1756-8722-4-29.
Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.
Shaib W, Mitchell K, Saif M
Yale J Biol Med. 2010; 83(1):27-33.
PMID: 20351979
PMC: 2844690.
Pancreatic VIPomas: subject review and one institutional experience.
Ghaferi A, Chojnacki K, Long W, Cameron J, Yeo C
J Gastrointest Surg. 2007; 12(2):382-93.
PMID: 17510774
DOI: 10.1007/s11605-007-0177-0.
Current concepts in functioning endocrine tumors of the pancreas.
Proye C, Lokey J
World J Surg. 2004; 28(12):1231-8.
PMID: 15517477
DOI: 10.1007/s00268-004-7645-4.
Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?.
De Menis E, Tulipano G, Villa S, Billeci D, Bonfanti C, Pollara P
J Endocrinol Invest. 2003; 26(4):359-63.
PMID: 12841545
DOI: 10.1007/BF03345185.
Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.
Case C, Wirfel K, Vassilopoulou-Sellin R
Med Oncol. 2002; 19(3):181-7.
PMID: 12482130
DOI: 10.1385/MO:19:3:181.
Expression of somatostatin mRNA in various differentiated types of gastric carcinoma.
Zhang Q, Ding Y
World J Gastroenterol. 2002; 4(1):48-51.
PMID: 11819230
PMC: 4767763.
DOI: 10.3748/wjg.v4.i1.48.
Pancreatic cancer: a review of emerging therapies.
Rosenberg L
Drugs. 2000; 59(5):1071-89.
PMID: 10852640
DOI: 10.2165/00003495-200059050-00004.
Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.
Rosenberg L
Int J Pancreatol. 1997; 22(2):81-93.
PMID: 9387029
DOI: 10.1007/BF02787465.
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
Ruszniewski P, Ducreux M, Chayvialle J, Blumberg J, Cloarec D, Michel H
Gut. 1996; 39(2):279-83.
PMID: 8977344
PMC: 1383312.
DOI: 10.1136/gut.39.2.279.
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R, Trautmann M, Creutzfeldt W, Benning R, Benning M, Neuhaus C
Gut. 1996; 38(3):430-8.
PMID: 8675099
PMC: 1383075.
DOI: 10.1136/gut.38.3.430.
Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R, Neuhaus C, Benning R, Schwerk W, Trautmann M, Joseph K
World J Surg. 1993; 17(4):511-9.
PMID: 8395752
DOI: 10.1007/BF01655111.
Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome.
Antonelli A, Gambuzza C, Bertoni F, BASCHIERI L
J Endocrinol Invest. 1993; 16(1):57-9.
PMID: 8383153
DOI: 10.1007/BF03345831.
